118 related articles for article (PubMed ID: 27238944)
1. Indian hepatitis C drug patent decision shakes public health community.
't Hoen EFM
Lancet; 2016 Jun; 387(10035):2272-2273. PubMed ID: 27238944
[No Abstract] [Full Text] [Related]
2. MSF pushes down price of generic hepatitis C drugs to new low level.
Wise J
BMJ; 2017 Nov; 359():j5054. PubMed ID: 29092825
[No Abstract] [Full Text] [Related]
3. Brazil's Fight against Hepatitis C - Universalism, Local Production, and Patents.
da Fonseca EM; Shadlen K; Bastos FI
N Engl J Med; 2019 Feb; 380(7):605-607. PubMed ID: 30763192
[No Abstract] [Full Text] [Related]
4. [Not Available].
Stingl W
MMW Fortschr Med; 2015 Jun; 157 Suppl 2():55. PubMed ID: 26048126
[No Abstract] [Full Text] [Related]
5. What price for a cure?
Taylor LE
R I Med J (2013); 2014 Jul; 97(7):16-8. PubMed ID: 25184174
[No Abstract] [Full Text] [Related]
6. Importation of generic hepatitis C therapies: bridging the gap between price and access in high-income countries.
Ghinea N; Lipworth W; Day R; Hill A; Dore GJ; Danta M
Lancet; 2017 Mar; 389(10075):1268-1272. PubMed ID: 27832868
[No Abstract] [Full Text] [Related]
7. What does it mean to put new hepatitis C drugs on a list of essential medicines?
Urrutia J; Porteny T; Daniels N
BMJ; 2016 Apr; 353():i2035. PubMed ID: 27106956
[No Abstract] [Full Text] [Related]
8. [Cost-effectiveness analysis of sofosbuvir-simeprevir regimens for chronic hepatitis C genotype 1 patients with advanced fibrosis].
Mar J; Mar-Barrutia L; Gimeno-Ballester V; San Miguel R
Med Clin (Barc); 2016 Jan; 146(2):61-4. PubMed ID: 26654558
[TBL] [Abstract][Full Text] [Related]
9. Questions hang over European patent for hepatitis C drug after ruling.
Stafford N
BMJ; 2016 Oct; 355():i5493. PubMed ID: 27758789
[No Abstract] [Full Text] [Related]
10. Medicaid Reimbursement for Oral Direct Antiviral Agents for the Treatment of Chronic Hepatitis C.
Ooka K; Connolly JJ; Lim JK
Am J Gastroenterol; 2017 Jun; 112(6):828-832. PubMed ID: 28374816
[No Abstract] [Full Text] [Related]
11. The very-rapid and the ultra-rapid virologic response to two treatment options in patients with chronic hepatitis C: an interim report of a prospective randomized comparative effectiveness study.
Yakoot M; Abdo AM; Yousry A; Helmy S
Drug Des Devel Ther; 2015; 9():6027-33. PubMed ID: 26628861
[TBL] [Abstract][Full Text] [Related]
12. Compulsory licences for direct acting antiviral drugs for hepatitis C.
Cattaneo A; Maciocco G
BMJ; 2016 Oct; 355():i5314. PubMed ID: 27707734
[No Abstract] [Full Text] [Related]
13. Sofosbuvir faces fresh patent challenge in Europe.
Stafford N
BMJ; 2017 Mar; 356():j1632. PubMed ID: 28360141
[No Abstract] [Full Text] [Related]
14. Restricted Access: State Medicaid Coverage of Sofosbuvir Hepatitis C Treatment.
Tumber MB
J Leg Med; 2017; 37(1-2):21-64. PubMed ID: 28910222
[TBL] [Abstract][Full Text] [Related]
15. HIV/HCV Co-infection: Overcoming Barriers to Treatment.
Gross C; Akoth E; Price A; Kattakuzhy S; Silk R; Rosenthal E
J Assoc Nurses AIDS Care; 2016; 27(4):524-9. PubMed ID: 26996983
[TBL] [Abstract][Full Text] [Related]
16. Therapy for hepatitis C genotype 3: moving forward.
Buti M; Llaneras J; Riveiro-Barciela M; Esteban R
J Viral Hepat; 2015 Sep; 22(9):683-90. PubMed ID: 25967352
[TBL] [Abstract][Full Text] [Related]
17. Screening and Treatment Program to Eliminate Hepatitis C in Egypt.
Waked I; Esmat G; Elsharkawy A; El-Serafy M; Abdel-Razek W; Ghalab R; Elshishiney G; Salah A; Abdel Megid S; Kabil K; El-Sayed MH; Dabbous H; El Shazly Y; Abo Sliman M; Abou Hashem K; Abdel Gawad S; El Nahas N; El Sobky A; El Sonbaty S; El Tabakh H; Emad E; Gemeah H; Hashem A; Hassany M; Hefnawy N; Hemida AN; Khadary A; Labib K; Mahmoud F; Mamoun S; Marei T; Mekky S; Meshref A; Othman A; Ragab O; Ramadan E; Rehan A; Saad T; Saeed R; Sharshar M; Shawky H; Shawky M; Shehata W; Soror H; Taha M; Talha M; Tealaab A; Zein M; Hashish A; Cordie A; Omar Y; Kamal E; Ammar I; AbdAlla M; El Akel W; Doss W; Zaid H
N Engl J Med; 2020 Mar; 382(12):1166-1174. PubMed ID: 32187475
[No Abstract] [Full Text] [Related]
18. Role Of Generics In Treatment Of Hepatitis C Infection.
Umar M; Akhter TS; Akbar I; Nisar G; Osama M; Akhter TS
J Ayub Med Coll Abbottabad; 2016; 28(4 Suppl 1):S890-S894. PubMed ID: 28782339
[TBL] [Abstract][Full Text] [Related]
19. Sofosbuvir initial therapy abandonment and manufacturer coupons in a commercially insured population.
Karmarkar TD; Starner CI; Qiu Y; Tiberg K; Gleason PP
Am J Manag Care; 2016 May; 22(6 Spec No.):SP191-7. PubMed ID: 27266948
[TBL] [Abstract][Full Text] [Related]
20. Ukrainian health authorities adopt hepatitis C project.
Devi S
Lancet; 2020 Jul; 396(10246):228. PubMed ID: 32711786
[No Abstract] [Full Text] [Related]
[Next] [New Search]
